english.prescrire.org > Prescrire International > N°235 - March 2022

n°235

March 2022

Issue Contents
Editorial

Free  Rational deprescribing

p.59

Marketing Authorisations


Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one F508del mutation

p.61-64
Respiratory symptoms alleviated in the short term

Molnupiravir in early covid-19 without signs of severe illness: value uncertain, including in unvaccinated patients at risk of severe disease

p.65-67

Delafloxacin (Quofenix°) in certain skin infections and certain types of pneumonia

p.67

Covid-19 vaccine booster dose: demonstrated clinical efficacy during Delta variant predominance, and no new safety signals

p.68-70

Secukinumab (Cosentyx°) in plaque psoriasis in children and adolescents

p.70-71

Burosumab (Crysvita°) in X-linked hypophosphataemia in adults

p.71

Perampanel (Fycompa°) in partial-onset or generalised epilepsy in certain children

p.72-73

Editors' opinion. Pragmatism

p.73

Baricitinib (Olumiant°) in atopic eczema in adults

p.73-74

Adverse Effects


Confusing tranexamic acid with a local anaesthetic: fatal spinal injections

p.75-76

Capsaicin: allergy in healthcare professionals

p.76

Stopping tramadol after prolonged use

p.77

Drug-induced tics: psychotropics and montelukast

p.77

INN Common stem: -azam, -azepam, -azolam

p.78

Perioperative benzodiazepines: a risk factor for persistent use

p.78

Outlook


Free  2021 Prescrire Drug Awards

p.79-81

Free  The Prescrire Awards for 2021

p.79-82

Free  2021 Information Awards

p.82

Free  Revision of European pharmaceuticals legislation

p.83

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe